Received Apr 7, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEP | HEP B (ENGERIX-B) | GLAXOSMITHKLINE BIOLOGICALS | 3 | UNK | — |
| HEP | HEP B (ENGERIX-B) | GLAXOSMITHKLINE BIOLOGICALS | 2 | UNK | — |
administer an Engerix-B vaccine and it was expired, it expired 09-Mar-2025; received Engerix B on 29th July 2024 and 23 OCT 2024; This non-serious case was reported by a nurse via call center representative and described the occurrence of expired vaccine used in a 12-year-old female patient who received HBV (Engerix B) (expiry date 09-MAR-2025) for prophylaxis. Co-suspect products included HBV (Engerix B) for prophylaxis. Concomitant products included Hepatitis b vaccine rHBsAg (yeast) (Engerix b). On 18-MAR-2025, the patient received the 3rd dose of Engerix B. On 23-OCT-2024, the patient received the 2nd dose of Engerix B. On 23-OCT-2024, not applicable after receiving Engerix B and an unknown time after receiving Engerix B, the patient experienced drug dose administration interval too long (Verbatim: received Engerix B on 29th July 2024 and 23 OCT 2024). On 18-MAR-2025, the patient experienced expired vaccine used (Verbatim: administer an Engerix-B vaccine and it was expired, it expired 09-Mar-2025). The outcome of the expired vaccine used and drug dose administration interval too long were not applicable. Additional Information: GSK Receipt Date: 19-MAR-2025 The patient received 2nd dose of Engerix B later than the recommended schedule, which led to lengthening of vaccination schedule. The patient received expired dose of Engerix B, which led to expired vaccine used.
ENGERIX B